.
Announcing Collaborative cancer cloud
Started by
acl
, Aug 20 2015 11:46 PM
1 reply to this topic
#1
acl
-
- Members
-
- 142 posts
Advanced Member
Posted 20 August 2015 - 11:46 PM
Diagnosed March 2014
Imatinib 400 mg. Summer 2014, Imatinib 300 mg.
% BCR-ABL
IS-NCN
06/01/16 0.18%
24/02/16 0.11%
23/03/16 0.13%
12/05/16 0.07%
13/07/16 0.17%
12/09/16 0.12%
21/19/16 0.15%
23/11/16 0.09%
20/12/16 0.11%
19/01/17 0.07%
21/02/17 0.07%
20/03/17 0.06%
20/04/17 0.06%
20/05/17 0.07%
20/06/17 0.06%
23/08/17 0.08%
22/12/17 0.04%
#2
hannibellemo
-
- Members
-
- 728 posts
Advanced Member
- LocationNorth Central Iowa
Posted 21 August 2015 - 11:30 AM
Relatively speaking I thought that was what our TKIs, as "targeted" therapies are.
Pat
"You can't change the direction of the wind but you can adjust your sails."
DX 12/08; Gleevec 400mg; liver toxicity; Sprycel 100mg.; CCyR 4/10; MMR 8/10; Pleural Effusion 2/12; Sprycel 50mg. Maintaining MMR; 2/15 PCRU; 8/16 drifting in and out of undetected like a wave meeting the shore. Retired 12/23/2016! 18 months of PCRU, most recent at Mayo on 7/25/17 was negative at their new sensitivity reporting of 0.003.<p>
1 user(s) are reading this topic
0 members, 1 guests, 0 anonymous users
